{"schema":"hottub-news/story/v1","story":"st_rinnrnf4krofsbiy2mia","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","title_en":null,"outlets":2,"brief":null,"page":"https://hottub.news/stories/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-rinnrnf4kr","count":2,"items":[{"id":"n_a4gsc35tvdphzu4tciqa","seq":1334264,"kind":"article","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/02/tmt-newswire/globenewswire/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635c4/2437930","published":"2026-10-02T11:03:00Z","seen":"2026-10-02T11:53:15Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"story":"st_rinnrnf4krofsbiy2mia","category":"economy-business","category_p":0.6800000071525574,"sentiment":"positive","tone":0.27000001072883606,"political":0.019999999552965164},{"id":"n_rinnrnf4krofsbiy2mia","seq":1327496,"kind":"press_release","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3373739/24675/en/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c-4.html","summary":"SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 62,900 shares of the…","published":"2026-10-02T11:00:00Z","seen":"2026-10-02T11:17:05Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:fate","us31189p1021"],"entities":[{"id":"Q30287119","name":"Fate Therapeutics","type":"org"}],"mentions":2,"story":"st_rinnrnf4krofsbiy2mia","category":"economy-business","category_p":0.6800000071525574,"sentiment":"positive","tone":0.5,"political":0.019999999552965164}]}